Rafael - Class B opened lower at $1.05, compared with its previous close of $1.09. In the last trading session, the stock traded between $1.05 and $1.12. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Rafael - Class B is now worth
$ 15.83
Resulting in a loss of
$ 84.17 (84.17%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.00 (+0.37%)
Day High
$1.12
Day Low
$1.05
Day Open
$1.05
Prev Close
$1.09
Volume
18,089
1W Return
1.77%
1M Return
-27.93%
3M Return
-43.72%
6M Return
-18.36%
1Y Return
-13.86%
Fundamentals
Market Cap ($ Mn)
56
PE Ratio
-
PB Ratio
1.77
PEG Ratio
-
ROE
-38.30%
ROCE
-38.77%
EPS (TTM)
$-0.18
Investment Returns
1 Week
1.77%
1 Month
-27.93%
3 Months
-43.72%
6 Months
-18.36%
9 Months
-8.83%
Financials
Quarterly
All values in $ Mn
0.4
Apr 25
0.3
Jul 25
0.2
Oct 25
0.2
Jan 26
0.2
Apr 26
0.2
Jul 26
Updates
11Nov
Pomerantz investigates Rafael Holdings after Phase 3 trial failure
Pomerantz LLP investigates Rafael Holdings for potential securities fraud. Stock fell 34.98% to $1.32 after Phase 3 trial failed primary endpoint. Trial evaluated Trappsol® Cyclo™ for Niemann-Pick Disease Type C. Investors advised to contact Pomerantz for class action participation.
2 days ago
4Nov
Pomerantz investigates Rafael Holdings after Phase 3 trial failure
Pomerantz LLP investigates Rafael Holdings for potential securities fraud. Stock fell 34.98% to $1.32 after Phase 3 trial missed primary endpoint. Investigation focuses on disclosures regarding Niemann-Pick Disease Type C treatment.
9 days ago
7Oct
Pomerantz probes Rafael Holdings after Trappsol Cyclo trial miss
Pomerantz LLP is investigating Rafael Holdings for potential securities fraud following a 34.98% drop in share price. Stock fell $0.71 to $1.32 on September 30, 2026, after Trappsol Cyclo missed its primary endpoint in Phase 3 trial. Primary analysis showed a non-significant difference of -0.81 points (p=0.19), though prespecified subgroup showed benefit. Company plans to submit NDA for Trappsol Cyclo to FDA in Q4 2026 despite primary endpoint miss.
1mo ago
11Jun
Rafael Holdings narrows Q3 loss to $(0.08) per share
Rafael Holdings narrowed its Q3 net loss to $(0.08) per share from $(0.19) a year ago, marking a 57.89% improvement. However, sales dropped 50.55% to $179.000 thousand, down from $362.000 thousand in the prior-year period.
5mo ago
10Jun
Rafael Holdings completes final Phase 3 study visits for NPC treatment
Rafael Holdings, Inc. completed the final 96-week visit in its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, involving 94 patients across 13 countries. Topline data is anticipated in the second half of 2026, alongside a planned NDA submission following a pre-NDA meeting with the FDA.
